华东医药(000963) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥10,735,787,899.82, representing a 3.12% increase compared to ¥10,410,809,128.72 in the same period last year[5]. - Net profit attributable to shareholders was ¥914,708,484.70, up 6.06% from ¥862,411,560.96 year-on-year[5]. - Basic earnings per share increased by 5.98% to ¥0.5224 from ¥0.4929 in the same period last year[5]. - The company achieved a revenue of 10.736 billion RMB, representing a year-on-year growth of 3.12% and a quarter-on-quarter increase of 2.95%[15]. - The net profit attributable to shareholders reached 915 million RMB, up 6.06% year-on-year, with a historical high of 897 million RMB in net profit after deducting non-recurring items, reflecting a 7.04% increase[15]. - The total comprehensive income for the current period is CNY 996,029,155.89, compared to CNY 900,835,055.99 in the previous period, reflecting an increase of approximately 10.6%[36]. - Operating profit for the current period is CNY 1,132,257,266.34, up from CNY 1,072,095,809.87, indicating a growth of about 5.6%[35]. Cash Flow and Assets - The net cash flow from operating activities decreased by 71.87%, amounting to -¥832,728,693.88, compared to -¥484,522,666.13 in the previous year[5]. - The company’s cash and cash equivalents decreased to ¥3,711,981,117.29 from ¥5,276,440,245.36, representing a decline of 29.66%[31]. - Accounts receivable increased significantly to ¥11,558,233,812.68 from ¥8,425,358,862.23, marking a growth of 37.80%[31]. - The company’s total assets reached ¥39,447,159,682.31, up from ¥37,879,046,367.15, indicating a growth of 4.15%[33]. - Cash flow from operating activities shows a net outflow of CNY -832,728,693.88, worsening from CNY -484,522,666.13 in the previous period[38]. - Cash and cash equivalents at the end of the period stand at CNY 3,421,628,769.05, an increase from CNY 3,105,149,941.54 in the previous period[38]. Research and Development - Research and development expenses rose by 82.99% to ¥51,537.69 million, compared to ¥28,163.98 million in the previous year[10]. - The company invested 880 million yuan in pharmaceutical R&D, a year-on-year increase of 49.60%, with direct R&D expenses of 600 million yuan, up 71.77%[20]. - Research and development expenses increased significantly to CNY 515,376,918.47 from CNY 281,639,751.64, marking an increase of about 83.1%[35]. Market Performance and Product Development - The core subsidiary, China Medical East, reported a revenue of 3.621 billion RMB, a year-on-year increase of 6.52%, and a net profit of 843 million RMB, up 12.20%[16]. - The CAR-T product, Zewokizumab, has been rapidly adopted in over 70 commercial insurance plans, significantly reducing patient costs and is expected to maintain high growth[16]. - The biosimilar drug, Selumetinib, has been prescribed in over 800 hospitals since its launch, indicating strong market performance and expected continued growth throughout the year[17]. - The new drug, Proglumetacin, has been included in the national medical insurance directory, with increasing hospital admissions, enhancing the company's competitive edge in the diabetes SGLT-2 segment[17]. - The acquisition of Guizhou Hengba Pharmaceutical has resulted in a revenue of 24.26 million RMB, with a net profit of 6.67 million RMB, marking over 100% growth year-on-year[17]. - The pharmaceutical commercial segment achieved a revenue of 6.934 billion RMB, reflecting a year-on-year growth of 3.23% and a net profit of 115 million RMB, up 7.33%[18]. - The aesthetic medicine segment faced growth pressure with a consolidated revenue of approximately 238 million yuan, a year-on-year decrease of 12.29%, but a quarter-on-quarter increase of 24.37%[19]. - The domestic aesthetic medicine subsidiary achieved a revenue of 254 million yuan, a year-on-year decline of 1.36%, and a quarter-on-quarter growth of 10.64%[19]. - The high-end hyaluronic acid product MaiLi®Extreme is set for commercialization in May 2025, featuring the innovative OxiFree™ technology[19]. - The company is advancing the registration and market launch of several new medical aesthetic products, including the V30 platform expected to receive approval by March 2025[29]. - The new filler MaiLi®Extreme received NMPA approval in January 2025, expanding the product line[29]. - The company is currently conducting safety follow-ups for the new hyaluronic acid filler MaiLi®Precise, which completed clinical trials in September 2024[29]. Equity and Shareholder Information - The company’s total equity attributable to shareholders increased by 4.33% to ¥24,059,686,522.62 from ¥23,060,051,397.36 at the end of the previous year[5]. - The number of ordinary shareholders at the end of the reporting period was 75,847, with no preferred shareholders having restored voting rights[11].